مشروع البحث: العلاج الدوائي لاعتلال الشبكية السكري (الأدوية المستجدة)
تحميل...
المساهمين
الممولين
رقم التعريف
24339
الباحث
يسرى محمد عبدالقادر هارون
الوصف
ABSTRACT
Diabetic retinopathy (DR) is a major cause f vision loss in patients with diabetes in many parts of the world, especially in developing countries. It is more common in patients with type 2 diabetes.
Vascular endothelial growth factor has been shown to contribute to the excessive vascular permeability that results in macular edema in people with diabetes. Thus a rational approach to treating macular edema in these patients would include the use of anti-VEGF agents.
This study was aimed to evaluate the effectiveness of repeated intravitreal administration of the anti-VEGF drug bevacizumab (Avastin)® (1.25mg/0.05cc) in Libyan patients diagnosed with diabetic retinopathy (DR) and attending the OT clinic (major surgery) for follow-up or treatment), based on the results of central macular thickness (CMT) that was measured with optical coherence tomography (OCT) measured at baseline and for three months (period of follow-up).
This is a prospective clinical study was undertaken in Tripoli Eye Hospital, Zawit Al Dahmani, Tripoli-Libya, included 43 patients diagnosed with diabetic retinopathy
In this study, the mean age of patients was 57.74 ± 10.39 years, and 48.84% were male, patients had a glycosylated hemoglobin (HbA1c) mean of 8.73 ± 2.04%. The mean duration of diabetes was 11.51 ± 6.58 years and 62.79% of the patients had uncontrolled hyperglycemia.
الكلمات الدالة
التقييم المستقبلي لفعالية إعطاء ثلاث حقن من عقار بيفاسيزوماب (أفاستين)® المضاد لعامل النمو البطاني الوعائي داخل الجسم الزجاجي في المرضى الليبيين الذين تم تشخيص إصابتهم باعتلال الشبكية السكري ويحضرون عيادة (جراحة كبرى) للمتابعة أو العلاج)، بناءً على نتائج سمك البقعة الصفراء المركزية (CMT) المقاسة بالتصوير المقطعي التوافقي البصري (OCT).